Longhua Street Conducts Supervision and Inspection of E-cigarette Enterprises

Dec.30.2024
Longhua Street Conducts Supervision and Inspection of E-cigarette Enterprises
Longhua Street conducts supervision and inspection on e-cigarette businesses to prevent illegal activities and ensure product quality and safety.

Longhua Street conducts supervision and inspection on e-cigarette companies, strengthening drug control and governance in the e-cigarette industry to eliminate illegal activities such as the addition of ethyl maltol to e-cigarettes.


During the operation, staff members will conduct thorough inspections on e-cigarette companies, checking their raw material procurement records to ensure legal sources. They will also focus on inspecting retail stores and verifying their business licenses. Product labels will undergo strict scrutiny to prevent false advertising that may mislead consumers, especially in order to avoid negative marketing influences on adolescents.


Staff members also visited relevant companies door-to-door to promote anti-drug efforts and explained the "Shenzhen Special Economic Zone Drug Control Regulations.


According to the relevant officials, a total of 27 businesses (retail stores) were inspected during this operation, which not only regulated business practices but also protected the health rights of residents. Longhua Street will continue to strengthen supervision and conduct regular inspections to urge e-cigarette companies to prioritize quality and safety, ensuring the legal development of e-cigarettes.


We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Exclusive|Suspected China Tobacco Nicotine Oral Film Product Surfaces on Social Media
Exclusive|Suspected China Tobacco Nicotine Oral Film Product Surfaces on Social Media
China Tobacco Jiangsu IC appears to have developed a nicotine oral film product under the "Nanjing" brand, according to images circulating on Chinese social media. If confirmed, this could potentially mark China Tobacco's first oral nicotine product targeting the domestic market. The product's authenticity has not been officially verified, and no nicotine pouch products have been approved for sale in China.
Special Report
Feb.09
PMI Faces Setback in India: Global Regulatory Fragmentation Complicates Its Smoke-Free Transition
PMI Faces Setback in India: Global Regulatory Fragmentation Complicates Its Smoke-Free Transition
India has reaffirmed its 2019 ban on e-cigarettes and heated tobacco devices, effectively blocking Philip Morris International (PMI) from launching IQOS in the country despite years of lobbying. Together with Taiwan, China’s conditional opening of heated tobacco products, and Japan’s planned 2026 excise tax hikes, these moves highlight increasingly divergent national regulatory pathways—an external uncertainty shaping PMI’s smoke-free growth trajectory.
Feb.12
FDA PMTA Roundtable: Ongoing Comprehensive Coverage by 2Firsts
FDA PMTA Roundtable: Ongoing Comprehensive Coverage by 2Firsts
Feb.11
Malaysian Langkawi marine police seize vape devices and e-liquid worth US$43,902
Malaysian Langkawi marine police seize vape devices and e-liquid worth US$43,902
In Langkawi, Malaysia, the Marine Police seized various vape devices and e-liquid valued at RM178,400 (about US$43,902.99). Authorities believe the goods were intended to be smuggled out to a neighboring country.
Jan.15 by 2FIRSTS.ai
Russian Lawmaker Says Bill on Full Vape Sales Ban Is Before State Duma
Russian Lawmaker Says Bill on Full Vape Sales Ban Is Before State Duma
Yaroslav Nilov, chair of the State Duma Committee on Labour, Social Policy and Veterans’ Affairs, said a bill proposing a full ban on vape sales is currently before the State Duma, though no final decision has yet been made. He said the initiative has been signed by representatives of almost all factions and noted that support for a full ban has also been voiced at the regional governor level. Nilov also said vape use in Russia is increasing while the age of consumers is declining.
Mar.12 by 2FIRSTS.ai
FDA Commissioner Stresses “Predictability” as Science Chief Addresses Industry Uncertainty
FDA Commissioner Stresses “Predictability” as Science Chief Addresses Industry Uncertainty
FDA Commissioner Marty Makary briefly appeared at the February 10 PMTA roundtable, underscoring the importance of regulatory predictability. At the close of the session, Office of Science Director Matthew Farrelly responded to industry concerns over review uncertainty, stating the agency will issue a written summary of feedback, while reiterating that no fixed quantitative risk benchmark governs authorization decisions.
Feb.11